Skip to main content
OpenTrials
Completed

NCT Number: NCT01354314

Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder

The purpose of this study is to see if paroxetine and fluconazole are safe and effective as a treatment for problems with memory, concentration, thinking, and judgment in people who are infected with HIV. Paroxetine is an antidepressant approved by the FDA to treat major depression. Fluconazole is an antifungal medication approved by the FDA to treat fungal infections.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Associated Neurocognitive Disorder Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

The Johns Hopkins Institute for Clinical and Translational Research, Adult Outpatient Clinical Research Unit

Baltimore, Maryland, 21287, United States

About this study

The study will be a 24 week double-blind, placebo-controlled 2x2 factorial design pilot Phase I/II study in 60 HIV+ individuals with HAND. Participants will be randomly assigned to one of four groups: 1) fluconazole 100 mg every 12 hours orally per day, 2) paroxetine 20mg every evening orally per day, 3) fluconazole 100mg every 12 hours orally per day and paroxetine 20mg every evening orally per day and 4) placebo.

Primary Aim: To obtain preliminary data to evaluate the efficacy of fluconazole and/or paroxetine to decrease CSF lipid and protein markers of oxidative stress [CSF ceramide and (C18:0 levels) and 3-nitrosylated proteins].

Secondary Aims:

i) To evaluate the safety and tolerability of fluconazole and/or paroxetine in HIV+ individuals with HAND ii) To evaluate the effect of fluconazole and/or paroxetine on neurocognitive performance in HIV+ individuals with HAND iii) To evaluate the effect of fluconazole and/or paroxetine on functional performance in HIV+ individuals with HAND iv) To evaluate the CNS penetration of fluconazole and paroxetine after 24 weeks of treatment v) To obtain preliminary data to evaluate the efficacy of fluconazole and/or paroxetine to improve abnormal imaging markers as measured by magnetic resonance spectroscopy (MRS) and arterial spin labeling

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • HIV+ based on ELISA and confirmed by either Western blot or plasma HIV RNA
  • capable of providing informed consent
  • age range: 18-65 years
  • presence of neuropsychological testing impairment as defined by performance at least 1.0 standard deviation below age-matched and education-matched controls on three or more independent neuropsychological tests at the screening visit, or performance at least 2.0 standard deviations below age-matched and education-matched controls on one independent neuropsychological test and at least 1.0 standard deviation below age-matched and education-matched controls on a second independent neuropsychological test at the screening visit
  • a stable HAART regimen for 3 months with no plans to change the antiretroviral regimen over the study period (confirmed by discussion with a patient's primary provider)
  • the following lab values within 2 weeks prior to entry: hemoglobin > 8.9 g/dl, absolute neutrophil count > 500 cells/mm3, platelet count > 50,000 cells/mm3, ALT < 2.5 X upper limit of normal, alkaline phosphatase < 3 X upper limit of normal, serum creatinine >= 2 X upper limit of normal
  • a negative serum or urine beta-HCG pregnancy test for all women of reproductive potential (have not reached menopause or undergone hysterectomy, oophorectomy, or tubal ligation)
  • neurological examination by a physician revealing no contraindication to a lumbar puncture. If an examination suggests a possible space-occupying brain mass lesion, neuroimaging with CT or MRI must confirm the absence of a mass lesion.

Exclusion criteria

  • current or past opportunistic CNS infection (fungal or non-fungal) at study entry
  • current systemic fungal infection
  • current or past use of fluconazole within 30 days of the screening visit
  • history or current clinical evidence of schizophrenia
  • history of chronic neurological disorder such as multiple sclerosis or uncontrolled epilepsy
  • active symptomatic AIDS defining opportunistic infection within 30 days prior to study entry
  • history of abnormal medical illness or current severe affective disorder (e.g., depression with suicidal intention) which in the opinion of the investigators would constitute a safety risk for patients or interfere with the ability of a patient to complete the study
  • treatment with anticoagulants including coumadin, heparin, or low molecular weight heparin which would be a contraindication for the lumbar puncture
  • HIV+ individuals with moderate or severe confounding illnesses
  • prior use of SSRI's within 1 month of screening
  • active substance abuse (illicit drugs and/or controlled medications) or active severe alcohol abuse, evidenced by history intake or urine toxicology at any visit prior to study entry (starting study medication)

Treatment and study plan

Fluconazole

Drug

One 100 MG capsule taken twice daily, 12 hour dosing

paroxetine

Drug

Two 10 MG capsules paroxetine once daily in the evening

Paroxetine and Fluconazole

Drug

One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening

Placebo

Drug

One capsule in the morning, three capsules in the evening

Primary outcomes

  1. Change in CSF Ceramide Between Baseline and Week 24 (C18:0 Levels) - Intent to Treat

    Time frame: 24 Weeks

    CSF lipid and protein markers of oxidative stress: Change in CSF ceramide (C18:0 levels) between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).

  2. Change in CSF Ceramide Between Baseline and Week 24 (C18:0 Levels) - Per Protocol

    Time frame: 24 Weeks

    CSF lipid and protein markers of oxidative stress: Change in CSF ceramide (C18:0 levels) between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).

  3. Change in CSF 3-nitrosylated Protein Levels Between Baseline and Week 24 - Intent to Treat

    Time frame: 24 Weeks

    CSF lipid and protein markers of oxidative stress: Change in 3-nitrosylated protein levels between baseline and week 24 for all participants for whom CSF data are available (intent to treat analysis).

  4. Change in CSF 3-nitrosylated Protein Levels Between Baseline and Week 24 - Per Protocol

    Time frame: 24 Weeks

    CSF lipid and protein markers of oxidative stress: Change in 3-nitrosylated protein levels between baseline and week 24 for participants with 90% or greater adherence to study drug and for whom CSF data are available (per protocol analysis).

Secondary outcomes

  1. Change in CSF sCD14 Between Baseline and Week 24 - Intent to Treat

    Time frame: 24 Weeks

    CSF immune and neuronal injury markers: Change in CSF sCD14 between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).

  2. Change in CSF sCD14 Between Baseline and Week 24 - Per Protocol

    Time frame: 24 Weeks

    CSF immune and neuronal injury markers: Change in CSF sCD14 between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).

  3. Change in CSF CD163 Between Baseline and Week 24 - Intent to Treat

    Time frame: 24 Weeks

    CSF immune and neuronal injury markers: Change in CSF CD163 between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).

  4. Change in CSF CD163 Between Baseline and Week 24 - Per Protocol

    Time frame: 24 Weeks

    CSF immune and neuronal injury markers: Change in CSF CD163 between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).

  5. Change in CSF Neurofilament Protein Light Chain (NFL) Between Baseline and Week 24 - Intent to Treat

    Time frame: 24 Weeks

    CSF immune and neuronal injury markers: Change in CSF neurofilament protein light chain (NFL) between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).

  6. Change in CSF Neurofilament Protein Light Chain (NFL) Between Baseline and Week 24 - Per Protocol

    Time frame: 24 Weeks

    CSF immune and neuronal injury markers: Change in CSF neurofilament protein light chain (NFL) between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).

  7. Change in CSF Neurofilament Protein Heavy Chain (pNFL) Between Baseline and Week 24 - Intent to Treat

    Time frame: 24 Weeks

    CSF immune and neuronal injury markers: Change in CSF neurofilament protein heavy chain (pNFL) between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).

  8. Change in CSF Neurofilament Protein Heavy Chain (pNFH) Between Baseline and Week 24 - Per Protocol

    Time frame: 24 Weeks

    CSF immune and neuronal injury markers: Change in CSF neurofilament protein heavy chain (pNFH) between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).

  9. Neurocognitive Performance: Trail Making A - Intent to Treat

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part A speed of completion (Z scores).

  10. Neurocognitive Performance: Trail Making A - Per Protocol

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part A speed of completion (Z scores).

  11. Neurocognitive Performance: Trail Making B - Intent to Treat

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part B speed of completion (Z scores).

  12. Neurocognitive Performance: Trail Making B - Per Protocol

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part B speed of completion (Z scores).

  13. Neurocognitive Performance: Grooved Pegboard, Dominant - Intent to Treat

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, dominant hand speed of completion (Z scores).

  14. Neurocognitive Performance: Grooved Pegboard, Dominant - Per Protocol

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, dominant hand speed of completion (Z scores).

  15. Neurocognitive Performance: Grooved Pegboard, Non-Dominant - Intent to Treat

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, non-dominant hand speed of completion (Z scores).

  16. Neurocognitive Performance: Grooved Pegboard, Non-Dominant - Per Protocol

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, non-dominant hand speed of completion (Z scores).

  17. Neurocognitive Performance: CalCAP, Choice - Intent to Treat

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Choice test, mean reaction time (Z scores).

  18. Neurocognitive Performance: CalCAP, Choice - Per Protocol

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Choice test, mean reaction time (Z scores).

  19. Neurocognitive Performance: CalCAP, Sequential - Intent to Treat

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Sequential test, mean reaction time (Z scores).

  20. Neurocognitive Performance: CalCAP, Sequential - Per Protocol

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Sequential test, mean reaction time (Z scores).

  21. Neurocognitive Performance: Symbol-Digit Test - Intent to Treat

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by Symbol-Digit Test score, number correct in 120 seconds (Z scores).

  22. Neurocognitive Performance: Symbol-Digit Test - Per Protocol

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by Symbol-Digit Test score, number correct in 120 seconds (Z scores).

  23. Neurocognitive Performance: Timed Gait - Intent to Treat

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by Timed Gait, three-trial average time (Z scores).

  24. Neurocognitive Performance: Timed Gait - Per Protocol

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by Timed Gait, three-trial average time (Z scores).

  25. Neurocognitive Performance: NPZ-8 - Intent to Treat

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by NPZ-8 scores calculated for all participants who completed the trial with measurable Baseline and Week 24 data for at least 6 of the 8 data points. The data points that comprise the NPZ-8 include timed gait, symbol-digit, grooved pegboard dominant and non-dominant, CalCAP Choice reaction time and Sequential reaction time, Trail-making Test A and B. The baseline to week 24 changes for each test were averaged to get each change in NPZ-8 score.

  26. Neurocognitive Performance: NPZ-8 - Per Protocol

    Time frame: 24 Weeks

    Baseline to Week 24 change in neurocognitive performance as measured by NPZ-8 scores calculated for all participants who completed the trial with measurable Baseline and Week 24 data for at least 6 of the 8 data points. The data points that comprise the NPZ-8 include timed gait, symbol-digit, grooved pegboard dominant and non-dominant, CalCAP Choice reaction time and Sequential reaction time, Trail-making Test A and B. The baseline to week 24 changes for each test were averaged to get each change in NPZ-8 score.

  27. Change in CES-D Score - Intent to Treat

    Time frame: 24 Weeks

    Functional assessment: Change in Center for Epidemiologic Studies Depression Scale (CES-D) score between baseline and week 24 for all participants for whom baseline and follow-up CES-D data are available (intent to treat analysis).

  28. Change in CES-D Score - Per Protocol

    Time frame: 24 Weeks

    Functional assessment: Change in Center for Epidemiologic Studies Depression Scale (CES-D) score between baseline and week 24 for all participants for whom baseline and follow-up CES-D data are available (per protocol).

Sponsors and collaborators

Lead sponsor

Johns Hopkins University

Other

Collaborators

  • National Institute of Mental Health (NIMH)

Registry information

Official study title

Pilot Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder (HAND)

Acronym: ParaFlu

Important dates

Study start
2010
Primary completion
2016
Study completion
2016
First posted
May 16, 2011
Registry last updated
Jun 9, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.